Novo Nordisk posts its first Ozempic sales decline in greater China as rival diabetes drugs gain approvals and price pressure intensifies.
By Andrew Silver SHANGHAI, Feb 5 (Reuters) - Sales of Novo Nordisk's blockbuster diabetes drug Ozempic in the greater China region fell for the first time last year, as it grapples with competition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results